Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 2011; 105(S 06): S1-S2DOI: 10.1160/THS11-03-0151 Thrombosis and Haemostasis Supplement Schattauer GmbH Education in atherothrombosis Robert F. Storey 1 Department of Cardiovascular Science, University of Sheffield, Sheffield, UK › InstitutsangabenArtikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen References 1 Collier J. Doctors, patients, and the pharmaceutical industry. Br Med J 2009; 338: b443. 2 House of Commons Health Committee.. The influence of the pharmaceutical industry. Fourth Report of Session 2004–05 2005; Available at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf. 3 Psaty BM. Conflict of Interest, Disclosure, and Trial Reports. J Am Med Assoc 2009; 301: 1477-1479. 4 Foster CJ, Prosser DM, Agans JM. et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-1598. 5 Andre P, Delaney SM, LaRocca T. et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406. 6 Evans DJW, Jackman LE, Chamberlain J. et al. The platelet P2Y12 receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009; 119: 116-122. 7 Patil SB, Jackman LE, Francis SE. et al. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arterioscler Thromb Vasc Biol 2010; 30: 2385-2391. 8 Hechler B, Gachet C. Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. Thromb Haemost 2011; (Suppl. 01) S3-S12. 9 Nurden AT. Platelets, Inflammation and Tissue Regeneration. Thromb Haemost 2011; (Suppl. 01) S13-S33. 10 Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; (Suppl. 01) S34-S42. 11 Hess K, Grant P. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; (Suppl. 01) S43-S54. 12 Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet Abnormalities in Diabetes Mellitus. Diabetes Vasc Dis Res 2010; 7: 251-259. 13 Ferreiro JL, Cequier AR, Angiolillo DJ. Antithrombotic Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease. Diabetes Vasc Dis Res 2010; 7: 274-288. 14 Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diabetes Vasc Dis Res 2010; 7: 260-273. 15 Storey RF. What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus?. Diabetes Vasc Dis Res 2010; 7: 249-250. 16 Tentzeris I, Siller-Matula J, Farhan S. et al. Non-genetic causes of platelet function variability. Thromb Haemost 2011; (Suppl. 01) S60-S66. 17 Yukhanyan L, Freynhofer M, Siller-Matula J, Schrör K, Huber K. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost 2011; (Suppl. 01) S55-S59. 18 Cattaneo M. Congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thromb Haemost 2011; (Suppl. 01) S67-S74. 19 Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 2011; (Suppl. 01) S75-S81.
